罕見血友病因素市場：現況分析與預測（2023-2030）

Rare Hemophilia Factors Market: Current Analysis and Forecast (2023-2030)

出版日期: 2023年12月30日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

由於老年人口的增加，預計罕見血友病因子市場在預測期內將以 5.2% 的複合年增長率增長。罕見出血性疾病包括一組比血友病不太常見的遺傳性凝血疾病。這些疾病通常發生在老年人身上。根據美國人口普查局的數據，到 2050 年，全球 65 歲及以上人口預計將達到 16 億，是 2018 年這一數字的兩倍多。同樣，世界衛生組織 (WHO) 估計，到 2050 年，60 歲及以上的人口數量將從 2017 年的 9.62 億增加近兩倍，達到 21 億。這些統計數據表明，全球老年人口正在顯著增加。

市場依類型分為因子 I、因子 II、因子 VII、因子 X、因子 XIII 等。由於這種缺陷的發生率很高，到 2022 年，因子 VII 細分市場將佔據大部分市場份額。根據美國國家出血性疾病基金會的數據，凝血因子 VII 缺乏症的發生率為每 30 萬至 50 萬人中 1 人，即每百萬人 2.5 人。凝血因子 VII 是凝血級聯中最重要的凝血蛋白□之一，關鍵參與啟動蛋白水解事件，最終導致凝血□生成、纖維蛋白沉積和血小板活化。凝血因子 VII 缺乏通常是體染色體隱性遺傳，男性和女性均等遺傳。因此，VII因子細分市場將在2022年佔據主要市場份額。

依治療方式，市場分為濃縮因子 VII 製劑、新鮮冷凍血漿、冷沉澱溶液等。由於藥品需求增加、對藥品安全選擇的需求、策略聯盟和合作研究以及創新產品的推出進一步推動了對智慧產品的需求，預計新鮮冰凍血漿細分市場將在預測期內增長。複合年增長率最高。當患者使用新鮮冰凍血漿而不是晶體或膠體進行復甦時，他們發生稀釋性凝血病的可能性較小。新鮮冷凍血漿可用於治療幾乎所有類型的罕見凝血因子缺乏症。因此，預計新鮮冷凍血漿領域在預測期內將在市場上獲得吸引力。

為了更了解罕見血友病因子產業的市場實施情況，將市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利、歐洲其他地區）），亞太地區根據全球分佈（中國、日本、印度、亞太地區其他地區）和世界其他國家進行分析。 2022年罕見血友病因子市場由北美主導。尖端和創新產品的可用性、人們對健康問題的認識不斷提高、該地區不斷增長的老年人口正在推動對治療的需求，以及對罕見出血性疾病藥物研發的投資增加。有幾個因素正在推動該地區的市場，包括：例如，2020 年，美國再生元製藥公司 (Regeneron Pharmaceuticals) 與 Intellia 合作，共同開發一種治療罕見遺傳性血液疾病（血液無法正常凝固）的潛在療法。按地區劃分，北美在 2022 年罕見血友病因子市場中佔據主導地位。

Rare bleeding disorders (RBDs) are autosomal recessive diseases including the inherited deficiencies of coagulation factors like fibrinogen, factor (F) II, III, FV, FVII, FX, FXI, FXIII, and others. These disorders are mainly caused by mutations or changes to the gene. The market is primarily driven by the increasing prevalence of rare blood disorders, such as hemophilia. These conditions are often inherited from affected parents and can result in symptoms such as uncontrolled bleeding episodes. As the global population ages, the incidence of rare blood disorders is expected to rise, thus fueling the demand for rare hemophilia factors therapeutics. Additionally, pharmaceutical advancements in the drugs have improved the safety and efficacy of rare hemophilia factors therapeutics, further driving market growth. Separate studies have found that aging patients encounter problems typical of old age compounded by hemophilia, which can cause bleeding in joints among other problems. Obesity is also a concern for people with hemophilia as they age something that can worsen joint bleeds and cause mobility issues.

The Rare Hemophilia Factors Market is expected to grow at a strong CAGR of 5.2% during the forecast period owing to the rising geriatric population. Rare bleeding disorders encompass a group of inherited blood clotting disorders that are less common than hemophilia. These disorders are often acquired by people of old age. According to the U.S. Census Bureau, the global population aged 65 and older is projected to reach 1.6 billion by 2050, more than double the population in 2018. Similarly, the World Health Organization (WHO) estimates that the number of people aged 60 and above will nearly triple by 2050, from 962 million in 2017 to 2.1 billion. These statistics indicate a significant increase in the geriatric population worldwide.

Based on type, the market is categorized into Factor I, Factor II, Factor VII, Factor X, Factor XIII, and others. The Factor VII segment held the majority share of the market in 2022 because of a high incidence of this deficiency. According to the National Bleeding Disorders Foundation, Factor VII deficiency has an incidence of 1 in 300,000-500,000 people or 2.5 cases per million. Factor VII is one of the most important coagulation proteases in the clotting cascade and is largely responsible for starting the proteolytic events that ultimately result in thrombin generation, fibrin deposition, and platelet activation. The deficiency is usually inherited in an autosomal recessive manner equally among men and women, both parents must carry the gene to carry it to their children. Hence, the Factor VII segment held a significant share of the market in the year 2022.

Based on treatment, the market is segmented into factor concentrates, fresh frozen plasma, cryoprecipitate, and others. The fresh frozen plasma segment is expected to grow with the highest CAGR during the forecast period owing to rising demand for medicines, the need for safe options for medicines, strategic collaborations and collaborations, and innovative product launches that have further increased the demand for intelligent products. When patients are revived with fresh frozen plasma rather than crystalloid or colloid, they are less likely to develop a dilutional coagulopathy. Fresh frozen plasma can be used as a treatment method for nearly all rare blood clotting factor deficiency types. Thus, the fresh frozen plasma segment is expected to gain prominence in the market in the forecast period.

For a better understanding of the market adoption of the rare hemophilia factors industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the market of rare hemophilia factors in 2022. Several factors such as the availability of cutting-edge and innovative products, growing awareness of health concerns, the rising geriatric population in the region are increasing the demand for therapeutics, and loaded investment in rare bleeding disorder drug discovery are driving the market in the region. For instance, in 2020, U.S.-based Regeneron Pharmaceuticals partnered with Intellia to co-develop potential treatments for rare blood disorders, which are genetic in fashion that prevent blood from clotting properly. North America dominated the rare hemophilia factors market among regions in the year 2022.

Some of the major players operating in the market include: Novo Nordisk A/S; Bayer AG; CSL; Takeda Pharmaceutical Company Limited; Bio Products Laboratory Ltd.; Octapharma AG; F. Hoffmann-La Roche Ltd; KM Biologics; GC Biopharma Corp.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Rare Hemophilia Factors Market
2.2. Research Methodology of the Rare Hemophilia Factors Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE RARE HEMOPHILIA FACTORS MARKET

6 RARE HEMOPHILIA FACTORS MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY TYPE

7.1. Factor I
7.2. Factor II
7.3. Factor VII
7.4. Factor X
7.5. Factor XIII
7.6. Others

8 MARKET INSIGHTS BY TREATMENT

8.1. Factor Concentrates
8.2. Fresh Frozen Plasma
8.3. Others

9 MARKET INSIGHTS BY REGION

9.1. North America
- 9.1.1. U.S.
- 9.1.2. Canada
- 9.1.3. Rest of North America
9.2. Europe
- 9.2.1. Germany
- 9.2.2. U.K.
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Rest of Asia-Pacific
9.4. Rest of World